About the Company
Built to Supply the World's Most Regulated Industry
Hemp Medicinal Farm Ltd was founded in 2023 with a single thesis: West Africa can become a reliable, compliant, cost-competitive source of pharmaceutical-grade cannabis. We are building that proof, one documented batch at a time.
2023
Founded
LI 2475
NACOC Licence — Feb 2026
50,000 kg
Pilot Annual Capacity
Capital
Initial Capital Secured · Series A Open
Foundation
Mission, Vision & Values
Mission
Advance Pharmaceutical Cannabis Science in Emerging Markets
To establish Ghana as a trusted, compliant source of pharmaceutical-grade cannabis by combining agronomic precision, rigorous quality systems, and transparent documentation that meets the standards of regulated pharmaceutical supply chains globally.
Vision
Position West Africa as a Research-Driven Cannabinoid Source
To establish Ghana as a trusted, compliant source of pharmaceutical-grade cannabis by combining agronomic precision, rigorous quality systems, and transparent documentation that meets the standards of regulated pharmaceutical supply chains globally.
Values
Science First. Documentation Always. No Shortcuts
We build compliance into our methodology from the first day of cultivation, not layered on at the point of export. Every decision is made with pharmaceutical buyer standards in mind. Transparency with partners and regulators is non-negotiable.
Ghana Advantage
Why Ghana. Why Now.
The combination of regulatory infrastructure, climate, and scientific capacity makes Ghana the most credible emerging market entry point for pharmaceutical cannabis production.
01
Equatorial Climate
Year-round cultivation cycles, optimal photoperiod, and natural growing conditions that European producers cannot replicate at comparable cost.
02
Regulatory First Mover
Ghana’s NACOC Act 1100 and LI 2475 framework is the first of its kind in West Africa. HMF Ltd holds an inaugural licence under this framework.
03
Cost Structural Advantage
Pharmaceutical-grade production at a fraction of European cost — without compromising on the documentation and compliance that buyers require.
04
Scientific Infrastructure
Growing academic and research capacity, with HMF Research serving as the scientific engine supporting continuous improvement in production methodology.
$133B
Cultivate specific cannabinoid profiles to meet exact requirements for pharmaceutical applications.
0
Prior licensed suppliers in West Africa
Feb
2026
LI 2475 framework activated
365
Days per year cultivation potential
The Opportunity
"First-Mover. Licensed. Production-Ready."
Ghana’s NACOC Act 1100 and LI 2475, launched February 2026, created the first pharmaceutical cannabis licensing framework in West Africa. HMF Ltd holds one of the inaugural licences.
Our Pillars
Six Operating Principles
Every decision at HMF Ltd is measured against these six pillars, which define how we cultivate, document, partner, and grow.
Pillar 01
Commitment to Quality
Pharmaceutical-grade standards are not aspirational for us — they are the baseline. Every batch is cultivated, processed, tested, and documented to meet the raw material requirements of regulated pharmaceutical manufacturers.
Pillar 02
Advanced Agricultural Technology
AI-augmented cultivation systems, precision nutrient management, and hybrid indoor/outdoor methodology enable us to maximise both yield and consistency while maintaining full traceability.
Pillar 03
Strict Compliance
We adhere to Ghanaian NACOC regulations, GACP principles, and are actively progressing our EU-GMP certification programme. Compliance is embedded in methodology — not applied retrospectively.
Pillar 04
Scientific Research
Our dedicated research division (HMF Research) drives continuous improvement in cannabinoid profiling, phenotype stabilisation, cultivation science, and regulatory pathway development.
Pillar 05
Economic Growth
Creating skilled employment, supporting local agricultural supply chains, and building Ghana’s pharmaceutical export capability — contributing to national economic diversification and scientific capacity.
Pillar 06
Global Health Access
By supplying reliable, affordable, pharmaceutical-grade cannabis materials to global manufacturers, HMF Ltd contributes to improving access to cannabis-based medicines for patients worldwide.
Built for the Long Term
From Founding to First Licence
Three years of deliberate groundwork — regulatory engagement, quality system development, and scientific infrastructure — before a single export shipment.
Founded 2023 — compliance-first from day one
NACOC licence granted February 2026 under LI 2475
Initial capital secured — Series A open
First pharmaceutical export shipments targeted 2026–2027
Company Timeline